<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417688</url>
  </required_header>
  <id_info>
    <org_study_id>201409006</org_study_id>
    <nct_id>NCT02417688</nct_id>
  </id_info>
  <brief_title>PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis</brief_title>
  <official_title>PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With [64]Cu-25%CANF-Comb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate feasibility of imaging Cu[64]-25%-CANF-Comb uptake in the atherosclerosis of
      the carotid artery of patients for whom carotid artery endarterectomy surgery is planned in
      comparison to the carotid artery for which intervention is not planned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, open-label baseline controlled imaging study designed to
      demonstrate feasibility of PET imaging of radiopharmaceutical nanoparticle
      Cu[64]-25%CANF-Comb uptake by PET-MR. Patients will undergo Cu[64]-25%CANF-Comb PET-MR
      imaging of both carotid arteries. Both carotid arteries will be imaged at the same time. We
      hope to demonstrate differences in PET SUV (Standardized Uptake Value) in the significantly
      atherosclerotic artery in patients who will be going to carotid endarterectomy surgery in
      comparison to the PET SUV in the artery that is not significantly diseased (ie; the artery
      that will not undergo surgery) . We also will determine whether PET SUV of the
      Cu[64]-25%CANF-Comb by the plaque correlates to the American Heart Association
      classifications of atherosclerosis and tissue presence of NPR-C in the ex vivo carotid
      endarterectomy specimen post surgery as measured by RT-PCR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET SUV (Standardized Uptake Value)</measure>
    <time_frame>22-26 hours</time_frame>
    <description>Difference in SUV between the carotid with atherosclerosis (carotid artery to be undergo surgery) and the carotid artery without significant disease (artery for which surgery is not planned).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Cu[64]-25%-CANF-Comb PET-MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 Î¼grams followed by PET-MR Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cu[64]-25%-CANF-Comb PET-MR</intervention_name>
    <description>Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR</description>
    <arm_group_label>Cu[64]-25%-CANF-Comb PET-MR</arm_group_label>
    <other_name>Cu[64]-25%-CANF-Comb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with carotid atherosclerosis

          -  Patients must be scheduled for carotid intervention (endarterectomy surgery)

          -  Signed informed consent.

        Exclusion Criteria:

          -  Unstable clinical conditions

          -  Pregnancy and lactation

          -  Inability to lie still for up to 60 min with arms down at sides for PET-MR imaging

          -  Unwilling to comply with study procedures and unavailable for the duration of the
             study.

          -  Pacemakers, brain aneurysm clip, shrapnel and other typical contraindications for MRI
             imaging.

          -  Inability to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela K Wooderd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Mohrman</last_name>
    <phone>(314) 747-4633</phone>
    <email>mohrmanm@mir.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Koudelis, RN</last_name>
    <phone>(314) 747-3876</phone>
    <email>koudelisd@mir.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University in St.Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela K Woodard, MD</last_name>
      <phone>314-362-9989</phone>
      <email>woodardp@mir.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela K Woodard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert J Gropler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed A Zayed, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Jim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongjian Liu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liu Y, Pressly ED, Abendschein DR, Hawker CJ, Woodard GE, Woodard PK, Welch MJ. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011 Dec;52(12):1956-63. doi: 10.2967/jnumed.111.089581. Epub 2011 Nov 2.</citation>
    <PMID>22049461</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Abendschein D, Woodard GE, Rossin R, McCommis K, Zheng J, Welch MJ, Woodard PK. Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med. 2010 Jan;51(1):85-91. doi: 10.2967/jnumed.109.066977. Epub 2009 Dec 15.</citation>
    <PMID>20008978</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Pamela Woodard, MD</investigator_full_name>
    <investigator_title>Professor of Radiology and Biomedical Engineering</investigator_title>
  </responsible_party>
  <keyword>carotid atherosclerosis, PET imaging agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

